|Company Name:||J & K SCIENTIFIC LTD. |
|Dutasteride Chemical Properties|
|Melting point ||242-250°C|
|storage temp. ||-20°C Freezer|
|Dutasteride Usage And Synthesis|
|Medicines to treat benign prostatic hyperplasia||On October 9, 2002, dutasteride that was developed by GSK was approved by the US Food and Drug Administration for the use in the treatment of prostate enlargement. |
On June 19, 2008, GSK announced that the FDA approved for the combination of idutasteride and tamsulosin in the treatment of prostate hyperplasia.
In China, on of two elderly men over the age of 60 have benign prostatic hyperplasia. It can cause urinary tract symptoms, including significant rise in frequency of urination, thin urine flow, bladder emptying difficulties, as well as nocturia. It even can cause serious complications, like acute urinary retention, reduce the patients’ life quality, and affect their social life.
Dutasteride is the first and the only dual 5α reductase inhibitor to be used in the treatment of prostatic hyperplasia. It can improve urinary system symptom, reduce the onset of acute urinary retention and the risk of prostate surgery. Tamsulosin is α receptor blockers. It can improve the symptom of prostate hyperplasia.
The human body has both type I reductase and type II 5α reductase. Type II mainly exists in the prostate. And type I mainly distributes in the liver and skin. 5α Reductase is the important reason that leads benign hyperplastic prostate disease continuous developing. It can make testosterone in patients’ prostate transform to DHT with stronger activity, which can cause prostate cells hyperplasia and prostate hypertrophy. Therefore, the inhibition of 5α reductase is the key to treat benign prostatic hyperplasia. And dutasteride can inhibit the type I and type II 5α reductase at the same time. Through this double inhibition mechanism, dutasteride can rapidly and continuously decrease prostate volume, significantly improve the urinary symptoms, reduce the risk of acute urinary retention and related prostate surgery, and bring benefit to patients with persistent, especially the middle and severe patients with benign prostatic hyperplasia.
The above information is edited by the Chemicalbook Geqian.
|Clinical evaluation||The approval of the US Food and Drug Administration bases on a multicenter randomized double-blind controlled clinical study for two years--the first long-term evaluation of the combination of dutasteride and alpha blockers in clinical research. The patients include moderate and severe prostate hyperplasia patients (age is greater than or equal to 50, prostatic volume (PV) ≥ 30cc, serum prostate specific antigen (PSA) level is 1.5~10 ng/mL, 5 mL/s < maximum urinary flow rate (Qmax) ≤15 mL/s, the minimum urine output ≥ 125 mL, the international prostate symptom score (IPSS) ≥ 12). Patients firstly take placebo for four weeks, and then randomly take both dutasteride 0.5 mg/day and tamsulosin 0.4 mg/day, or only take dutasteride 0.5 mg/day, tamsulosin 0.4 mg/day.|
The clinical study shows that the treatment effect of the combination of dutasteride is better than single treatment after twelve and twenty-four months. The most common adverse reactions of this product are impotence, decreased libido, breast disease (including breast augmentation, swelling), ejaculatory dysfunction, and dizziness.
|Uses||Dutasteride is 5α reductase inhibitor.|
|Chemical Properties||White Crystalline Solid|
|Usage||Used in the treatment of benign prostatic hyperplasia. Dual inhibitor of 5a-reductase isoenzymes type 1 and 2; structurally related to Finasteride.|
|Usage||Used in the treatment of benign prostatic hyperplasia. Dual inhibitor of 5α-reductase isoenzymes type 1 and 2; structurally related to Finasteride.|
|Usage||antihypertensive, ACE inhiibitor|
|Usage||Dutasteride is a dual inhibitor of 5α-reductase isoenzymes type 1 and 2; structurally related to Finasteride (F342000). Dutasteride is used in the treatment of benign prostatic hyperplasia.|
|Dutasteride Preparation Products And Raw materials|